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Abstract
Background: We investigated whether 9p21 polymorphisms are associated with cardiovascular events in a group
of 611 patients enrolled in the Medical, Angioplasty or Surgery Study II (MASS II), a randomized trial comparing
treatments for patients with coronary artery disease (CAD) and preserved left ventricular function.
Methods: The participants of the MASS II were genotyped for 9p21 polymorphisms (rs10757274, rs2383206,
rs10757278 and rs1333049). Survival curves were calculated with the Kaplan–Meier method and compared with the
log-rank statistic. We assessed the relationship between baseline variables and the composite end-point of death,
death from cardiac causes and myocardial infarction using a Cox proportional hazards survival model.
Results: We observed significant differences between patients within each polymorphism genotype group for
baseline characteristics. The frequency of diabetes was lower in patients carrying GG genotype for rs10757274,
rs2383206 and rs10757278 (29.4%, 32.8%, 32.0%) compared to patients carrying AA or AG genotypes (49.1% and
39.2%, p = 0.01; 52.4% and 40.1%, p = 0.01; 47.8% and 37.9%, p = 0.04; respectively).
Significant differences in genotype frequencies between double and triple vessel disease patients were observed
for the rs10757274, rs10757278 and rs1333049. Finally, there was a higher incidence of overall mortality in patients
with the GG genotype for rs2383206 compared to patients with AA and AG genotypes (19.5%, 11.9%, 11.0%,
respectively; p = 0.04). Moreover, the rs2383206 was still significantly associated with a 1.75-fold increased risk of
overall mortality (p = 0.02) even after adjustment of a Cox multivariate model for age, previous myocardial
infarction, diabetes, smoking and type of coronary anatomy.
Conclusions: Our data are in accordance to previous evidence that chromosome 9p21 genetic variation may
constitute a genetic modulator in the cardiovascular system in different scenarios. In patients with established CAD,
we observed an association between the rs2383206 and higher incidence of overall mortality and death from
cardiac causes in patients with multi-vessel CAD.
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Background
Coronary heart disease (CHD), including acute myocar-
dial infarction, are leading causes of morbidity and
mortality worldwide [1]. Lifestyle and environmental
factors play an important role in their development,
but genetic inheritance appears to be strongly involved
[2]. Recently, genome-wide association studies have
revealed single nucleotide polymorphisms (SNP) on
chromosome 9p21 that confer susceptibility to coronary
artery disease (CAD) and myocardial infarction (MI) in
some populations such as Caucasians from Northern
Europe [3], North American [4], Italian [5] and Belgian
[6]. Among the Han Chinese population, Lin et al.
observed that the chromosome 9p21 had a significant
association with carotid atherosclerosis in a gender-
specific manner [7]. Moreover, meta-analysis of the
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relationship between chromosome 9p21.3 polymorph-
isms and CAD has provided stronger evidences for the
association [8,9].
9p21.3 is a chromosomal region relatively replete of
open reading frames (ORF) and the closest genes are a
cluster consisting of CDKN2A-ARF-CDKN2B (cyclin-
dependent kinase N2A and N2B), MTAP, and ANRIL.
The linkage disequilibrium (LD) structure of this gen-
omic locus varies depending on the studied population,
and different LD blocks are described between asso-
ciated SNP and ORF in the region. This locus has been
associated with tumor suppression, cell proliferation,
senescence, apoptosis [10,11], all features implicated in
atherogenesis and now with CAD [12]. The mechanisms
involved remain unclear but studies in mice have pro-
vide direct evidence that the CAD risk interval has a
pivotal role in regulation of cardiac Cdkn2a/b expres-
sion, and suggest that this region affects CAD progres-
sion by altering the dynamics of vascular cell
proliferation [13].
At the same time, genetic variants around the same
genes were associated with an increased risk of type 2
diabetes mellitus [14-16] atherothrombosis [17] and is-
chemic stroke [18]. All these data suggest that there may
be common pathogenic mechanisms involved in these
apparently disparate diseases. On the other hand, Plant
et al. showed that there was no association between
rs10757278 and stroke status based on the presence or
absence of angiographically demonstrated CAD in non-
stroke controls. They supposed an association of this
genomic region with ischemic stroke independent of its
effect on CAD, suggesting an additional stroke-specific
pathophysiological relationship [19].
In this report, we analyzed whether the rs10757274,
rs2383206, rs10757278 and rs1333049 polymorphisms
are associated with cardiovascular events in a group of
611 patients enrolled in the MASS II [20,21], a study
that compared therapeutic strategies for individuals with
multi-vessel CAD established. This will explore the asso-
ciation of 9p21 genetic variants in individuals with
already established and severe CAD.
Methods
Study population
Studied patients were selected from the prospective, ran-
domized and controlled Medicine, Angioplasty, or Sur-
gery Study II (MASS II), which was designed to compare
medical treatment, angioplasty or stent (percutaneous
coronary intervention, PCI), and myocardial revasculari-
zation (coronary artery bypass grafting, CABG) in
patients with multi-vessel stable CAD with preserved left
ventricular function [20,21].
Methodological details were described by Hueb et al.
Briefly, patients with angiographically documented
proximal multivessel coronary stenosis of more than
70% by visual assessment and documented ischemia
were considered for inclusion. Ischemia was documented
by either stress testing or the typical stable angina as-
sessment of the Canadian Cardiovascular Society (CCS)
(class II or III). Patients were enrolled and randomized if
there was agreement on the part of the surgeon and
interventionist that revascularization could be attained
by either strategy. Exclusion criteria included unstable
angina or acute MI requiring emergency revasculariza-
tion, ventricular aneurysm requiring surgical repair, left
ventricular ejection fraction of <40%, a history of PCI or
CABG, and single-vessel disease. Patients were also
excluded: if they had a history of congenital heart dis-
ease, valvular heart disease, or cardiomyopathy; if they
were unable to understand or cooperate with the proto-
col requirements or to return for follow-up; or if they
had left main coronary artery stenosis of 50% or more,
or suspected or known pregnancy or another coexisting
condition that was a contraindication to CABG or PCI.
In this trial, all patients were placed on an optimal med-
ical regiment consisting of a stepped-care approach
using nitrates, aspirin, beta-blockers, calcium channel
blockers, angiotensin-converting enzyme inhibitors, or a
combination of these drugs, unless contraindicated.
Hydroxymethylglutaryl-coenzyme A reductase inhibitors
were also prescribed, along with a low-fat diet on an in-
dividual basis. Patients were then randomized to con-
tinue with aggressive medical therapy (MT) alone or to
undergo PCI or CABG concurrently with MT [20,21].
Two thousand seventy-six candidates who had indica-
tions for myocardial revascularization were evaluated
from May 1995 to May 2000. Of these, 611 patients were
eligible and met all entry criteria to be randomly
assigned to 1 of the 3 therapeutic groups: medical treat-
ment (n = 203), PCI (n = 205), and CABG (n = 203). The
primary end-point of this study was to compare the fre-
quencies of major cardiac events, such as acute MI,
overall mortality or refractory angina requiring revascu-
larization procedures.
All subjects gave informed consent, and the Ethics
Committee of the Heart Institute of the University of
Sao Paulo - Brazil approved the study.
Data collection
The beginning of treatment was considered to be the
randomized date and patients were studied by the
intention to treat principle. The follow-up time for all
patients in this study was 5 years with clinical visits con-
ducted in a 6-month interval. The collected demographic
and laboratory data included age, gender, angiographic
findings and traditional risk factors, such as history of
previous coronary events, hypertension, diabetes, BMI
(body mass index), severity of angina, smoking status,
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and cholesterol and triglycerides profile. Blood samples
were obtained from each participant at randomization.
Adverse and other clinical events were tracked from
randomization. Patients underwent a symptom-limited
treadmill exercise test at baseline and every year until
the end of the study, unless contraindicated. Symptoms
of angina were graded according to their severity and
were considered refractory only when patients had been
treated with full anti-ischemic therapies. Myocardial in-
farction was defined as the presence of significant new
Q waves in at least 2 ECG leads or symptoms compat-
ible to MI associated with creatinine kinase-MB eleva-
tions. Cardiac mortality was defined when patient died
of MI.
Genotyping
Genomic DNA was extracted from peripheral blood leu-
kocytes by means of a standard salting-out procedure.
Genotyping assays were run as submicroliter PCR-based
assay on array tape that is a continuous plastic tape
used in conjunction with a flexible configuration of
dispensing, pipetting, sealing and detection modules
manufactured by Douglas Global Array. This method is
especially suitable for processes based on PCR and a
modified allele-specific PCR assay as described by Mya-
kishev et al. [22] was used. We obtained an average
genotyping success rate of more than 95% and an aver-
age genotyping accuracy of more than 98% by re-
genotyping 32 samples.
Statistical analysis
Data are presented as mean ± SD for continuous variable
and as frequencies for categorical variables. Differences
in baseline characteristics among groups were analyzed
using ANOVA for continuous variables and chi-square
test for categorical variables. Survival curves were calcu-
lated with the Kaplan–Meier method and differences be-
tween the curves were evaluated with the log-rank
statistic. We assessed the relationship between baseline
variables and composite end-point events using a Cox
proportional hazards survival model adjusted for age,
previous MI, diabetes, smoking and type of coronary
anatomy. Hazard ratios (relative risks) with 95% confi-
dence intervals (CIs) demonstrate the risk for combined
events. Biochemical data and BMI were adjusted for age
and gender.
The Hardy-Weinberg equilibrium (HWE) analyses
were conducted with Haploview 4.0 for Windows and
genotypic distributions for the rs10757274, rs2383206,
rs10757278 and rs1333049 polymorphisms were in ac-
cordance with the HWE (p = 0.32, p = 0.82, p = 0.64,
p = 0.99, respectively). Multiple testing correction was
not performed and our sample number only provide
80% power to detect an association with overall
mortality with an effect size of 3.8 for the rs10757274 G
variant allele, 3.4 for the rs2383206 G variant allele, 3.9
for the rs10757278 G variant allele, and 3.9 for the
rs1333049 G variant allele. A value of p ≤ 0.05 was con-
sidered significant for comparisons and statistical ana-
lyses were performed with SPSS 13.0 for Windows.
Results
Baseline clinical characteristics according to genotypes
Of the 611 patients (mean age 60 ± 9), 92 (15.1%) were
female and 519 (84.9%) male. Patients in all three thera-
peutic groups were similar with respect to general char-
acteristics, severity of angina, use of medication, history
of MI, diabetes mellitus, or hypertension. The character-
istics of 611 patients assigned to one of three groups for
multivessel disease are available in previous study
[20,21].
The variant allele frequencies were 51%, 59%, 51%,
and 48% for the rs10757274 (N= 498), rs2383206
(N= 495), rs10757278 (N= 496), and rs1333049
(N= 507) polymorphisms on chromosome 9p21, respect-
ively; and the distribution of the genotypes are shown in
Table 1. There were significant differences between
patients within each polymorphism genotype group for
baseline characteristics (Table 1).
The frequency of diabetes was lower in patients carry-
ing GG genotype for rs10757274, rs2383206 and
rs10757278 (29.4%, 32.8%, 32.0%) compared to patients
carrying AA or AG genotypes (49.1% and 39.2%,
p = 0.01; 52.4% and 40.1%, p = 0.01; 47.8% and 37.9%,
p = 0.04; respectively). Higher frequency of diabetes was
observed in patients carrying GG genotype for
rs1333049 (49.6%) compared to patients carrying CC or
GC genotypes (34.5% and 36.4%, p = 0.03). Smoking,
hypertension and previous myocardial infarction fre-
quencies presented significant difference among
rs10757274, rs2383206 and rs1333049 genotypes, re-
spectively (Table 1).
In respect to coronary anatomy, the rs10757274 GG
genotype, rs10757278 GG genotype and rs1333049 CC
genotype had higher frequencies of triple-vessel disease
(68.3%, p = 0.05; 67.2%, p = 0.02; 64.0%, p = 0.03; respect-
ively) (Table 1).
Cardiovascular end-points
With respect to the end points of death (overall mortal-
ity), death from cardiac causes, myocardial infarction, re-
fractory angina requiring either angioplasty or surgery,
we observed a higher frequency of overall mortality in
patients with the GG genotype for rs2383206 compared
to patients with AA and AG genotypes (19.5%, 11.9%,
11.0%, respectively; p = 0.04, Table 2).
A Cox proportional hazards model adjusted for age,
previous myocardial infarction, diabetes, smoking and
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Table 1 Baseline clinical characteristics according to polymorphisms
rs10757274 P rs2383206 P rs10757278 P rs1333049 P
N = 498 N= 495 N= 496 N = 507
Variables AA AG GG AA AG GG AA AG GG CC GC GG
Frequency 112 260 126 84 237 174 115 253 128 139 253 115
Age (years) 60.1±9.3 59.4±9.0 59.3±8.9 0.73 60.5±8.7 59.1±9.3 59.5±9.1 0.50 59.9±9.3 59.5±9.2 59.4±9.3 0.91 59.1±9.2 60.0±9.2 59.4±9.0 0.65
Men (%) 65.2 66.9 71.4 0.55 65.5 65.4 71.3 0.42 64.3 66.8 70.3 0.60 70.5 65.6 67.8 0.61
Smoking (%) 34.8 28.5 42.9 0.02 28.6 31.6 37.4 0.30 32.2 30.4 39.8 0.18 40.3 28.9 33.0 0.07
Hy (%) 67.9 55.4 59.5 0.08 73.8 50.2 62.1 <0.01 67.0 53.8 60.2 0.05 60.4 54.2 65.2 0.12
DM (%) 49.1 39.2 29.4 0.01 52.4 40.1 32.8 0.01 47.8 37.9 32.0 0.04 34.5 36.4 49.6 0.03
BMI (kg/m2) 27.1±4.0 27.2±4.2 27.3±4.0 0.94 27.4±3.9 27.0±4.1 27.4±4.2 0.49 27.3±4.0 26.9±4.1 27.6±4.2 0.26 27.5±4.2 27.0±4.1 27.2±4.2 0.48
MI (%) 42.9 42.3 54.0 0.08 41.7 42.6 51.7 0.13 47.8 41.1 53.1 0.07 54.0 40.7 48.7 0.03
TC (mg/dL) 219.8±48.5 225.5±51.5 222.7±47.0 0.58 220.9±50.5 223.1±51.7 225.8±45.6 0.73 220.0±50.8 226.0±51.8 223.7±44.0 0.56 223.0±43.9 225.7±51.6 219.3±49.9 0.52
LDLc (mg/dL) 144.6±45.5 149.9±47.6 144.6±37.0 0.44 144.8±46.8 148.3±47.7 148.3±37.3 0.81 145.7±47.6 149.9±46.7 145.6±35.8 0.58 145.7±36.4 149.6±47.0 145.2±45.6 0.60
HDLc (mg/dL) 36.4±10.8 37.1±9.8 38.0±10.1 0.47 35.6±8.7 37.3±10.4 38.2±11.0 0.18 36.3±10.7 37.0±9.4 38.711.7 0.20 38.7±11.5 37.3±10.0 36.0±8.9 0.14
TG (mg/dL) 197.7±112.5 194.3±123.8 196.0±110.2 0.96 204.9±116.6 188.3±115.2 195.3±121.5 0.53 194.9±112.7 193.4±115.9 195.1±125.9 0.99 195.1±124.2 191.4±116.0 198.2±112.2 0.87
PCI (%) 29.5 33.1 37.3 0.51 27.4 35.0 35.1 0.23 33.9 30.8 39.8 0.30 38.8 32.0 32.2 0.43
CABG (%) 32.1 34.2 34.9 36.9 29.5 37.4 29.6 34.8 33.6 35.3 33.6 33.0
CT (%) 38.4 32.7 27.8 35.7 35.4 27.6 36.5 34.4 26.6 25.9 34.4 34.8
2-Vessel (%) 44.6 49.2 31.7 0.05 45.2 48.5 36.8 0.06 47.8 47.4 32.8 0.02 36.0 46.2 52.2 0.03
3-Vessel (%) 55.4 50.8 68.3 54.8 51.5 63.2 52.2 52.6 67.2 64.0 53.8 47.8
N=number of samples genotyped.
Data are shown as mean ± standard deviation, unless otherwise indicated.
Hy=Hypertension; DM=Diabetes mellitus; MI=Myocardial infarction; TC= Total Cholesterol; LDLc = Low density lipoprotein; HDLc=High density lipoprotein; TG= Triglycerides; PCI=Angioplasty;
CABG=Revascularization; CT=Clinical treatment; 2 or 3-vessel = coronary anatomy disease.
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type of coronary anatomy (double-vessel or triple-vessel)
demonstrated that the rs2383206 was still significantly
associated with a 1.75-fold increased risk of overall mor-
tality (p = 0.02) (Table 3). In the same model, age and
previous myocardial infarction were associated to a 1.06
and 1.82-fold increased risk of overall mortality, respect-
ively. In addition, age and previous myocardial infarction
variables were associated to increased risk of overall
mortality in the models including rs10757274,
rs10757278 and rs1333049 polymorphisms (Table 3).
Gender, hypertension and randomized therapeutic op-
tion were also included in the Cox regression models
regarding rs2383206, but observed results or increase
risk of overall mortality were not changed.
In Figure 1, survival curves show significant differ-
ences regarding overall mortality for the SNP rs2383206
when we analyze separated (AA, AG, GG; p = 0.034) or
grouped genotypes (AA+AG, GG; p = 0.010). We also
observed a significant difference for death from cardiac
causes among same SNP, but only with grouped geno-
types (p = 0.030). In both cases, overall mortality and
death from cardiac causes, the GG genotype was asso-
ciated with increased risk of death.
Discussion
Significant associations between rs10757274, rs2383206,
rs10757278 and rs1333049 polymorphisms and diabetes
and coronary artery disease were observed in patients
with well-known multi-vessel CAD. Furthermore, our
results suggested a significant difference in overall mor-
tality and death from cardiac causes according to the
rs2383206 in this patient sample that already presents
well established risk factors and multivessel coronary ar-
tery disease.
Currently, genome-wide association identified a single re-
gion on chromosome 9p21.3 associated with CHD and MI
risks [3,4] independently of traditional risk factors including
age, gender, obesity, smoking, hypertension and hyperlipid-
emia [8,9]. Besides, Musunuru et al. have proposed that risk
alleles at 9p21.3 locus may have pleiotropic effects on MI,
CAD and stroke risks, possibly through their influence on
platelet reactivity [23]. Helgadottir et al. [4] identified the
rs10757278 that showed significant association with MI
Table 3 Cox proportional-hazards model for overall
mortality
P OR 95.0% CI
Age 0.00 1.06 1.03 1.09
Diabetes mellitus 0.08 1.51 0.94 2.42
Smoking 0.39 1.26 0.74 2.14
Coronary anatomy 0.33 1.28 0.77 2.13
Previous myocardial infarction 0.02 1.76 1.09 2.84
rs10757274 0.31 1.31 0.78 2.21
P OR 95.0% CI
Age 0.00 1.06 1.03 1.09
Diabetes mellitus 0.15 1.41 0.88 2.27
Smoking 0.68 1.12 0.65 1.92
Coronary anatomy 0.28 1.32 0.79 2.20
Previous myocardial infarction 0.02 1.82 1.12 2.95
rs2383206 0.02 1.75 1.08 2.82
P OR 95.0% CI
Age 0.00 1.06 1.03 1.09
Diabetes mellitus 0.19 1.38 0.85 2.22
Smoking 0.77 1.09 0.63 1.89
Coronary anatomy 0.17 1.43 0.86 2.40
Previous myocardial infarction 0.02 1.81 1.11 2.94
rs10757278 0.32 1.30 0.78 2.18
P OR 95.0% CI
Age 0.00 1.06 1.03 1.09
Diabetes mellitus 0.11 1.46 0.91 2.32
Smoking 0.29 1.33 0.78 2.24
Coronary anatomy 0.15 1.44 0.88 2.37
Previous myocardial infarction 0.03 1.71 1.06 2.73
rs1333049 0.32 1.36 0.74 2.49
Coronary anatomy: double-vessel versus triple-vessel disease.
Table 2 Cardiovascular end-points
rs10757274 P rs2383206 P rs10757278 P rs1333049 P
N=498 N=495 N=496 N=507
Events AA AG GG AA AG GG AA AG GG CC GC GG
Refractory angina 17.9% 18.5% 15.9% 0.82 19.0% 16.0% 17.2% 0.81 19.1% 17.0% 16.4% 0.84 15.8% 17.4% 19.1% 0.79
PCI 9.8% 13.8% 9.5% 0.35 9.5% 12.2% 10.3% 0.73 11.3% 11.9% 10.9% 0.96 10.8% 12.6% 11.3% 0.84
MI 8.9% 7.7% 7.9% 0.92 10.7% 8.0% 6.3% 0.47 9.6% 7.9% 6.3% 0.63 6.5% 7.5% 9.6% 0.65
Cardiac death 8.9% 9.2% 11.1% 0.81 8.3% 7.2% 13.2% 0.11 8.7% 7.5% 13.3% 0.18 11.5% 9.5% 7.0% 0.47
Total death 11.6% 13.8% 17.5% 0.42 11.9% 11.0% 19.5% 0.04 12.2% 13.0% 17.2% 0.45 15.8% 14.6% 11.3% 0.57
Total events 25.9% 29.2% 26.2% 0.73 27.4% 25.3% 27.4% 0.74 26.1% 27.3% 27.3% 0.97 25.9% 28.9% 25.2% 0.71
N=number of samples genotyped.
Refractory angina = requiring either angioplasty or surgery; PCI = angioplasty; MI =myocardial infarction; Cardiac death = death from cardiac causes; Total
death = overall mortality; Total events = refractory angina requiring angioplasty or surgery + angioplasty +myocardial infarction + death from cardiac
causes + overall mortality.
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risk and that approximately 21% of individuals in the
population are homozygous for this variant with estimated
risk of suffering MI equal 1.64 times as great as that of
non-carriers. McPherson et al. [3] identified 2 SNPs in the
same genomic region, rs10757274 and rs2383206, both
associated with risk, in 6 independent studies comprising
more than 23,000 individuals and with a population-
attributable fraction of 10% to 15%. Moreover, the Well-
come Trust Case Control Consortium [24] identified
rs1333049 in this region, also showing strong association
with CHD risk and a study that combined the Wellcome
Trust Case Control Consortium data with data from Ger-
many also confirmed the chromosome 9 region and iden-
tified 6 additional novel candidate genes for CHD [12].
In our study, we observed the association of the SNP
rs2383206 to CAD within a group of patients with multi-
vessel coronary disease that can reveal higher incidence of
death depending on its genotype. The reports cited here
have provided evidences of increased risk or susceptibility
to develop CAD in case–control studies and our findings
have showed significant differences of cardiovascular events
within a sick population.
Regarding baseline clinical characteristics, our results
showed association of all studied SNPs with prevalence of
type 2 diabetes mellitus in these patients. In fact, the GG
genotypes for the rs10757274, rs2383206 and rs10757278
suggested protection while the GG genotype for the
rs1333049 indicated risk. Recent reports have discussed
the association of these loci on chr9p21 with type 2 dia-
betes mellitus suggesting the sharing of pathogenic
mechanisms with heart disease [14-16]. Studying the asso-
ciation between the SNP rs2383206 and CAD, Doria et al.
observed increased CAD risk in the presence of poor gly-
cemic control in type 2 diabetes [25]. Gori et al. [26] have
confirmed that rs2891168 and rs10811661 are independ-
ently associated with MI and type 2 diabetes, respect-
ively in an Italian population as reported by the
PROCARDIS group [27].
Figure 1 Survival curves for the rs2383206 polymorphism.
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In a recent study, Wang et al. observed a significant
association of homozygous CC genotype for the
rs1333049 with CAD in non-diabetic Chinese Han
population but not in type 2 diabetic patients. Besides,
they have demonstrated that CC or GC genotype car-
riers had a more severe plaque progression than GG
genotype carriers [28]. The GRACE genetics study has
provided evidence that the association of rs1333049 with
recurrent MI or cardiac death was independent of all
other risk factors [29]. Another recent report showed
that the 9p21 variant rs10116277 is independently asso-
ciated with all-cause mortality after primary CABG sur-
gery in Whites and significantly improves the predictive
value of the logistic EuroSCORE [30]. Here, we find that
not only the rs1333049 CC genotype is more associated
with serious CAD but also rs10757278 GG genotype;
both are related to triple-vessel disease.
Finally, with respect to the end points, there was
higher incidence of overall mortality in patients with GG
genotype for rs2383206, which remained significantly
associated with a 1.75-fold increased risk of overall mor-
tality (CI 95%= 1.08 – 2.82) even after adjustment of a
Cox multivariate model. The association of this SNP
with death can be observed in the survival curves where
not only overall mortality was affected but cardiac death
too.
There are some limitations in our study. First, we were
not able to perform replication studies in a similar sam-
ple because there are very few studies similar to MASSII
in the literature. However, our main findings are in ac-
cordance to previous studies including a current study
published in this journal which confirmed a strong asso-
ciation of the 9p21.3 locus with MI particularly in
patients with a positive family history [30]. Second, our
sample size only provide 80% power to detect an associ-
ation with overall mortality with an effect size of 3.4-3.9
for the polymorphisms and correction for multiple test-
ing was not performed. We recognize that such effects
are highly unlikely for common genetic variants and re-
affirm the need for the development of increased sam-
ples of multivessel CAD patients with long-time follow-
up period for the identification of more modest effects.
In addition, we observed that diabetes and smoking did
not have significant effects in the multivariate analysis
for overall mortality, as well as gender and hypertension,
probably because our sample is composed of more se-
vere patients. Third, it is not possible to completely ex-
clude the interaction between the use of concomitant
drugs, other genetic markers, ethnicity and other covari-
ates on our findings [31-34].
Conclusions
Our data are in accordance to previous evidence that
chromosome 9p21 genetic variation may constitute a
genetic modulator in the cardiovascular system in differ-
ent scenarios, including in patients with established
CAD, by revealing an association between the rs2383206
and higher incidence of overall mortality and death from
cardiac causes in patients with multi-vessel CAD.
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